As big pharma backs away, Alnylam sees deja vu By: CNBC.com News April 16, 2014 at 15:23 PM EDT This week the headline appeared to have some tough news for RNA companies, but Alnylam remains undeterred about the potential of its treatments. Read More >> Related Stocks: Alnylam Pharmaceuticals Dicerna Pharmaceutic JPMorgan Chase & Co Merck & Co Novartis Ag ADR Regulus Therapeutics Rogers Corp Sanofi-Aventis S.A. ADR